by s2desi5_ksqtherapeutics | Oct 2, 2017 | Uncategorized
– World class executive team led by CEO David Meeker and CSO Frank Stegmeier – – Proprietary CRISPRomics™ Drug Discovery Engine Pinpoints the Best Therapeutic Nodes of Diseases; Product Insights Being Translated into Drug Candidates – Cambridge, Mass., October 2, 2017...
by s2desi5_ksqtherapeutics | Sep 25, 2018 | Uncategorized
– Industry Leader Brings Expertise in Medical, Clinical and Regulatory Affairs in Drug Development – Cambridge, Mass., September 25, 2018 – KSQ Therapeutics today announced the appointment of Richard A. Moscicki, MD, to the company’s Board of Directors. Dr. Moscicki...
by s2desi5_ksqtherapeutics | Sep 28, 2018 | Uncategorized
– Company’s Pipeline Spans Three Oncology Drug Categories: Adoptive T‑Cell Therapies, Immuno-Oncology Monotherapies and Targeted Therapies – – Proprietary CRISPRomics™ Discovery Engine Has Yielded 12 Oncology Drug Discovery Programs in 12 Months – CAMBRIDGE, Mass. –...
by s2desi5_ksqtherapeutics | Oct 15, 2019 | Uncategorized
– CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs – – KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTILTM cell franchise – ZUG,...
by s2desi5_ksqtherapeutics | Oct 28, 2019 | Uncategorized
– Posters at AACR-NCI-EORTC and SITC illustrate genome-wide, in vivo T-cell approach to identify and validate novel therapeutic immuno-oncology targets – CAMBRIDGE, Mass., October 28, 2019 – KSQ Therapeutics, a biotechnology company using CRISPR technology to enable...
